Article Figures & Data
Figures
- FIGURE 1.
Whole-body images of 2 subjects printed at different brightness levels. Subject on left was scanned from head to feet. Subject on right was scanned in opposite direction to visualize the body before high amounts of 11C-PIB accumulate in urinary bladder. There is no 11C-PIB binding to Aβ deposits in these healthy volunteers as they lack Aβ aggregates. Radioactivity on images is due to biodistribution of tracer in the course of its metabolism and elimination.
- FIGURE 2.
Time–activity curves of liver (A), gallbladder (B), upper large intestine (C), and kidneys (D). Dots indicate measured data; line is a 3-exponential fitting to those measurements, except in C, upper large intestine, where the line is average of measurements until 40 min and after that it represents physical decay of 11C.
- FIGURE 3.
Excretion of 11C-PIB into urine expressed as percentage of excreted radioactivity out of the injected dose. Dots are individual measurements, and line is the fitted exponential in-growth formula, which starts at zero.
Tables
- TABLE 1
Residence Times in Source Regions and Number of Subjects Contributing to Each Source
Source organ Residence time (h) No. of subjects Brain 0.012 5 Gall bladder content 0.016 7* Stomach 0.002 3 Upper large intestine 0.011 3 Heart content 0.002 7 Heart wall 0.004 3 Kidneys 0.012 4 Liver 0.107 6 Lungs 0.008 3 Muscle 0.066 3 Cortical bone 0.021 6 Spleen 0.002 5 Urinary bladder content 0.022 16 Remainder of body 0.206 — ↵* Four subjects were imaged at 0–40 min to represent the dynamic phase and 3 subjects were scanned at steady state at approximately 100 min after tracer injection.
Target organ μGy/MBq Adrenals 3.97 Brain 3.10 Breasts 2.33 Gallbladder wall 41.5 Lower large intestine wall 3.00 Small intestine 3.62 Stomach 3.46 Upper large intestine wall 9.00 Heart wall 4.76 Kidneys 12.6 Liver 19.0 Lungs 3.39 Muscle 1.83 Ovaries 3.24 Pancreas 4.06 Red marrow 2.84 Bone surface 2.71 Skin 2.10 Spleen 4.31 Testes 2.44 Thymus 2.54 Thyroid 2.35 Urinary bladder wall 16.6 Uterus 3.52 Total body 2.83 Effective dose 4.74 μSv/MBq* ↵* Effective dose is the organ-weighted sum of target organ absorbed doses according to ICRP 60 (15).
Jump to section
Related Articles
Cited By...
- Phase 1 Evaluation of 11C-CS1P1 to Assess Safety and Dosimetry in Human Participants
- Repurposing bromocriptine for A{beta} metabolism in Alzheimers disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimers disease with presenilin 1 (PSEN1) mutations
- The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with ({+/-})-11C-YJH08 PET
- Biodistribution and Radiation Dosimetry of 11C-Nicotine from Whole-Body PET Imaging in Humans
- Human Radiation Dosimetry for the N-Methyl-D-Aspartate Receptor Radioligand 11C-CNS5161
- Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology
- Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B
- Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging
- Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements
- Radiation Dosimetry of {beta}-Amyloid Tracers 11C-PiB and 18F-BAY94-9172
- 1-11C-Methyl-4-Piperidinyl-N-Butyrate Radiation Dosimetry in Humans by Dynamic Organ-Specific Evaluation